Sprycel (dasatinib) — Medica

Initial criteria

• Patient is age ≥ 18 years.
• Patient has metastatic or unresectable disease.
• Patient has an activating KIT mutation.
• Patient has tried at least one systemic regimen.

Reauthorization criteria

• Patient continues to meet initial criteria.

Approval duration

1 year